MEDEZE Wins Frost & Sullivan’s 2025 Company of the Year Award

MEDEZE Group Public Company Limited has been awarded the prestigious 2025 Southeast Asia Company of the Year Recognition by Frost & Sullivan for its exemplary contributions to the fields of stem cell banking and regenerative medicine. This acknowledgment comes as a result of MEDEZE’s commitment to innovation, regulatory leadership, and effective clinical alignment within the healthcare sector.

Frost & Sullivan’s assessment process is thorough, focusing on two primary criteria: strategy effectiveness and strategy execution. MEDEZE demonstrated significant strengths in both areas, showcasing its ability to not only meet market demands but also to execute its strategies with precision. According to Unmesh Lal, Vice President of Healthcare & Life Sciences at Frost & Sullivan, “MEDEZE is redefining stem cell banking in Southeast Asia through full-spectrum, clinically aligned solutions, leveraging innovation and GMP-grade infrastructure.”

MEDEZE’s approach includes a vertically integrated model that encompasses various aspects of cell banking, including biological material collection, diagnostics, cell processing, and clinical applications. This comprehensive system ensures that the company maintains high standards of quality and regulatory compliance throughout its operations in Southeast Asia.

Innovation plays a crucial role in MEDEZE’s success. The company has developed proprietary technologies, such as the AutoXpress System, which automates the processing of umbilical cord blood, and the Chibuya Robotic Stem Cell Culture System, recognized as the world’s first full-room cleanroom automation. These advancements allow MEDEZE to manufacture therapeutic-grade products at scale, enhancing its capacity to serve a growing market.

MEDEZE’s focus on international accreditation further solidifies its standing in the regenerative medicine sector. It is the only Thai stem cell bank accredited by the US-based Association for the Advancement of Blood & Biotherapies (AABB), in addition to holding ISO 9001 and ISO 22716 certifications. These credentials underscore the company’s dedication to adhering to the highest safety and quality standards across both therapeutic and wellness applications.

With a robust network of over 260 hospital partnerships, including prominent institutions like Samitivej Hospital Group and Bangkok Hospital, MEDEZE is instrumental in Thailand’s ADMP Sandbox clinical program. The organization is currently involved in trials targeting conditions such as osteoarthritis, degenerative disc disease, skin rejuvenation, colorectal cancer, and immune enhancement. These initiatives position MEDEZE as a frontrunner in the commercialization of licensed cell therapies in Southeast Asia, with plans to launch by 2026.

Frost & Sullivan recognizes MEDEZE for setting new standards in competitive strategy, innovation, and market responsiveness. The company’s operational model, financial health, and commitment to sustainable growth exemplify its leadership in biotechnology, placing MEDEZE at the forefront of the region’s shift towards licensed regenerative therapies.

Each year, Frost & Sullivan honors a company that demonstrates outstanding strategy development and execution, resulting in substantial improvements in market share and customer satisfaction. This recognition highlights organizations that are reshaping their industries through innovative practices and a commitment to excellence.

MEDEZE’s achievements reflect not only its internal capabilities but also its broader impact on the healthcare landscape in Southeast Asia, promising advances that could transform patient care and treatment options across the region.